Literature DB >> 32526625

Multimorbidity and SARS-CoV-2 infection in UK Biobank.

Yogini V Chudasama1, Clare L Gillies2, Karen Appiah2, Francesco Zaccardi2, Cameron Razieh3, Melanie J Davies3, Thomas Yates3, Kamlesh Khunti2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32526625      PMCID: PMC7271848          DOI: 10.1016/j.dsx.2020.06.003

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


× No keyword cloud information.
Evidence to date has focused on assessing the individual prevalence and impact of comorbidities in patients with coronavirus disease (COVID-19) [1]. We aimed to investigate the pattern of the most prevalent combinations of multimorbidity (i.e. presence of two or more pre-existing chronic diseases) in those infected with SARS-CoV-2. UK Biobank (https://www.ukbiobank.ac.uk/) is a large prospective cohort of middle-aged adults. Assessments were conducted between 2006 and 2010. Self-reported medical information based on physician diagnosis was included to determine long-term cardiovascular, non-cardiovascular, or mental health conditions. Three sources were used to select conditions; first: the Quality and Outcomes Framework reports the most common diseases in the UK [2]; second: a large UK based study containing 40 recommended disorders [3]; third: a systematic review on multimorbidity indices including 17 conditions [4]. Based on these we selected 36 chronic conditions (supplementary). The ten most prevalent co-occurring chronic conditions from these 36 (threshold ≥5 participants) are presented. SARS-CoV-2 test results from Public Health England were linked to UK Biobank database [5]. Data was available between March 16 and May 03, 2020. Descriptive analyses were performed. From 502,543 UK Biobank participants, 3002 have been tested for SARS-CoV-2 infection in England, of which 1073 (36%) tested positive; median age was 70 (interquartile range 59–76) years, 54% were males, 85% were white, 5% South Asian, 6% black, and 4% other ethnicity. At baseline, 31% (n = 329) had multimorbidity (two or more pre-existing chronic conditions). The most prevalent combinations of multimorbidity were predominantly clustered around cardiometabolic conditions: diabetes and hypertension (78% of participants with diabetes had hypertension), angina and hypertension (72% of participants with angina), stroke and hypertension (69% of participants with stroke), myocardial infarction (MI) and hypertension (66% of participants with MI), depression and hypertension (45% of participants with depression), MI and angina (45% of participants with MI). Within non-cardiovascular diseases, common combinations included irritable bowel syndrome (IBS) and asthma (27% of participants with IBS), migraine and asthma, and mental-ill health (particularly depression) in combination with cardiometabolic conditions, Fig. 1 .
Fig. 1

The most common co-occurring chronic diseases at baseline assessment of UK Biobank participants with multimorbidity and tested positive for SARS-CoV-2 infection (n = 329), between March 16 and May 03, 2020.

The most common co-occurring chronic diseases at baseline assessment of UK Biobank participants with multimorbidity and tested positive for SARS-CoV-2 infection (n = 329), between March 16 and May 03, 2020. A limitation of this analysis is that data on pre-existing chronic diseases was collected at baseline, and participants may have since developed other chronic conditions; and possible selection bias. However, these results are important as they provide better understanding of the number and type of chronic disease combinations most commonly found in those testing positive for SARS-CoV-2 infection. As more data emerges on those with multimorbidity, it is crucial to clarify the burden of severity and mortality in people with COVID-19.

Funding/support

The National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC-EM). Data was analysed using UK Biobank application number 36371.

Ethical approval and informed consent

All participants gave written informed consent prior to data collection. UK Biobank has full ethical approval from the NHS National Research Ethics Service (16/NW/0274).

Data access and responsibility

The data that support the findings of this study are available from UK Biobank project site, subject to registration and application process. Further details can be found at https://www.ukbiobank.ac.uk.

Declaration of competing interest

None.
  5 in total

Review 1.  The measurement of multiple chronic diseases--a systematic review on existing multimorbidity indices.

Authors:  Claudia Diederichs; Klaus Berger; Dorothee B Bartels
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-11-26       Impact factor: 6.053

2.  Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.

Authors:  Karen Barnett; Stewart W Mercer; Michael Norbury; Graham Watt; Sally Wyke; Bruce Guthrie
Journal:  Lancet       Date:  2012-05-10       Impact factor: 79.321

3.  Setting performance targets in pay for performance programmes: what can we learn from QOF?

Authors:  Tim Doran; Evangelos Kontopantelis; David Reeves; Matthew Sutton; Andrew M Ryan
Journal:  BMJ       Date:  2014-03-04

4.  Dynamic linkage of COVID-19 test results between Public Health England's Second Generation Surveillance System and UK Biobank.

Authors:  Jacob Armstrong; Justine K Rudkin; Naomi Allen; Derrick W Crook; Daniel J Wilson; David H Wyllie; Anne Marie O'Connell
Journal:  Microb Genom       Date:  2020-07

5.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.

Authors:  Jing Yang; Ya Zheng; Xi Gou; Ke Pu; Zhaofeng Chen; Qinghong Guo; Rui Ji; Haojia Wang; Yuping Wang; Yongning Zhou
Journal:  Int J Infect Dis       Date:  2020-03-12       Impact factor: 3.623

  5 in total
  4 in total

1.  Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K.

Authors:  Nita G Forouhi; Kamlesh Khunti; Yogini V Chudasama; Francesco Zaccardi; Clare L Gillies; Cameron Razieh; Thomas Yates; David E Kloecker; Alex V Rowlands; Melanie J Davies; Nazrul Islam; Samuel Seidu
Journal:  BMC Infect Dis       Date:  2021-09-04       Impact factor: 3.090

Review 2.  Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension.

Authors:  Bin Zhou; Pablo Perel; George A Mensah; Majid Ezzati
Journal:  Nat Rev Cardiol       Date:  2021-05-28       Impact factor: 32.419

3.  Shift work is associated with increased risk of COVID-19: Findings from the UK Biobank cohort.

Authors:  Yaqoot Fatima; Romola S Bucks; Abdullah A Mamun; Isabelle Skinner; Ivana Rosenzweig; Guy Leschziner; Timothy C Skinner
Journal:  J Sleep Res       Date:  2021-03-08       Impact factor: 5.296

4.  Association between household size and COVID-19: A UK Biobank observational study.

Authors:  Clare L Gillies; Alex V Rowlands; Cameron Razieh; Vahé Nafilyan; Yogini Chudasama; Nazrul Islam; Francesco Zaccardi; Daniel Ayoubkhani; Claire Lawson; Melanie J Davies; Tom Yates; Kamlesh Khunti
Journal:  J R Soc Med       Date:  2022-02-04       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.